Fixing an HCP Problem in a Commercially Licensed Product

Fixing an HCP Problem in a Commercially Licensed Product

When a biopharmaceutical company and their CMO could not determine the cause of rising HCP ELISA values, they approached Dr. Kevin Van Cott of Prolytix for answers. Read the case study to find out how we used high-resolution mass spectrometry to identify the underlying cause of batch rejections and stop the bleeding of time and money.

  • Mass spectrometry has superior power, compared to techniques like HCP-ELISA, to uncover the root cause of an HCP problem.
  • Using mass spectrometry earlier would have saved considerable resources

Download the Case Study: